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an average LOS of only 4.62 days. The total cost per hospital-
ization was also lowest for HCV at $11,797 and was signiﬁcantly
higher for HIV ($14,595, P < 0.0001). The total cost per hospi-
talization for HIV and HCV co-infections was $14,686. The
total cost of non-HCV or HIV hospitalizations was nearly half
($8,859). The probability of death associated with HCV, HIV,
and co-infected HCV and HIV was 3.5%, 5.1% and 5.6%
respectively while the probability of death associated with non-
HIV or HIV-related hospitalizations was only 2.1%. CONCLU-
SIONS: This is one of few studies to quantify differences in
inpatient costs and outcomes associated with HCV, HIV, and
HCV and HIV co-infection in a multi-payer US population.
Hospitalizations related to HCV and HIV co-infections were
longer and more expensive compared to those related to HCV
only. Policy and other decision makers should be aware of this
burden as strategies to allocate resources are developed.
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OBJECTIVES: Central venous catheter (CVC) is the main reason
for intrahospitalary bacteraemia. The prevalence of nosocomial
Catheter-related bacteraemia (CRB) hospitalwide is 6.58%.
Gram-positive microorganisms are responsible for more than
50% of these bacteraemia. This study aimed to clear manage-
ment of non-permanent CRB caused by Gram-positives and
resource use associated. METHODS: A multicenter, observa-
tional, transversal cost study was carried out, where every proven
CRB was recorded. CRB was deﬁned as a positive culture from
the distal end of the catheter plus at least a positive peripheral
blood culture involving isolations of the same micro-organism-.
The study was performed from the hospital perspective; therefore
only medical direct costs (€2007) were included: hospitalization
cost, diagnosis test cost, and analytical cost. Costs were obtained
from Spanish databases. Qualitative and quantitative descriptive
analyses were made for all the variables. RESULTS: A total of 23
proven CRB and more than 400 suspected catheter infections,
which did not meet criteria inclusion, were identiﬁcated, in 5
Spanish hospitals. Average age was 60.17 (SD 13,799) years old,
being 52.2% women. Coagulase-negative Staphylococcus was
the micro-organism responsible for the 73.9% of CRB, mostly
S. epidermidis (56.5%). S. aureus was isolated in 17.4% cases.
Vancomycin was the most frequently prescribed antibiotic
(47.8%), followed by teicoplanin (26.1%), with a mean duration
of 8.48 (SD 4481) days. Nevertheless, 52% patients required
new antibiotics as cloxaciline (20%), vancomycin (20%) and
teicoplanin (20%), due to treatment failure, with a mean extra-
hospital treatment duration of 5.7 (SD 4547) days. Mean time
to CRB resolution-time since initial clinical signs until fever
clearance- was 6.65 (SD 4.608) days, with a mean cost per
episode of €4375.42. The 95% of costs are attributable to length
of hospitalization, with a mean cost per episode of €4150.81,
therefore, being the driver cost. CONCLUSIONS: CRB is asso-
ciated with a profound increase in resource use. Prevention, early
diagnosis, and intervention for non-permanent catheter related
bacteraemia might result in cost savings for the National Health
System.
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OBJECTIVES: Previous economic analyses of gram + cSSTIs
have not included costs related to outpatient parenteral antibiotic
therapy (OPAT). The objective of this analysis was to develop a
core model framework and appropriate inputs to estimate
medical and drug costs within both inpatient and outpatient
components of care for treating gram + cSSTIs and serve as a
basis for comparing vancomycin with newer antibiotics.
METHODS: A 4-week decision model was developed to estimate
the direct total, inpatient, and outpatient costs of treating
gram + cSSTIs from a payer perspective taking into account suc-
cesses, failures, and adverse events. Published literature provided
clinical inputs and resource use data, with validation by expert
opinion. Cost data was derived from literature and standard CPT
coding reimbursements. Sensitivity analyses tested efﬁcacy, com-
plication rates, length of stay, and other resource use parameters.
Costs were reported in 2008US$. RESULTS: Drug acquisition
cost for 14 days of vancomycin 1gm IV q12hr was $257;
however, the total 4-week cost of treatment including clinical
failures, complications, and OPAT ranged from $8,214–$13,133
(66–86% of cost inpatient, 14–33% outpatient). Important
vancomycin cost drivers beyond the inpatient stay ($1219/day)
included OPAT cost ($175/day), line placement and complica-
tions related to OPAT ($739/patient), physician visits ($192/
patient), injection supply/admin costs ($183/patient), and lab
work ($98/patient). Antibiotics with favorable dosing/admin-
istration proﬁles reduced OPAT costs and provided opportunity
for early discharge. The most sensitive model variables for total
cost were the MRSA efﬁcacy rate, length of hospital stay, days of
OPAT and line complications. CONCLUSIONS: The model
framework and results suggest that the costs associated with
generic vancomycin for treatment of cSSTIs may be substantial,
with a signiﬁcant portion of costs extending into the outpatient
arena. The budget impact of newer antimicrobials should be
evaluated in the context of total medical cost offsets from both
inpatient and outpatient perspectives.
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OBJECTIVES: To understand real-world impacts of venous leg
ulcer (VLU) on direct medical costs and productivity in the US
and the UK. METHODS: This prospective, observational, multi-
center study enrolled 112 patients with VLU (US: 76 and UK:
36). Patients were followed for 12 weeks or until all their ulcers
healed in 2007 and 2008. Data were gathered on health care
resources used at the study site as well as outside the study site
(using patient diaries). Standard national data sources were used
to assign unit costs to the resources used. The mean direct
medical cost was estimated from the US payer, US provider, and
UK National Health Service (NHS) perspectives separately and
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stratiﬁed by ulcer healing status. Work productivity loss was
captured weekly by the Work Productivity and Activity Impair-
ment (WPAI) Questionnaire [1] speciﬁc for VLU. RESULTS: The
mean direct medical cost of treating VLU during the study period
was estimated to be $1772 per patient for US payers, $1294 for
US providers, and £1502 in the UK. The largest direct medical
cost component was for professional services, or labor (approxi-
mately 70%), followed by dressing, compression bandages, and
medications. Patients who had at least one ulcer not healed at the
end of study had higher mean costs compared to those patients
who had all ulcers healed ($2250 vs. $1012 from the US payer
perspective, $1625 vs. $862 from the US provider perspective,
and £1770 vs. £965 from the UK NHS perspective). Over the
12-week study duration, more reductions in work productivity
loss and activity impairment were found in the healed group vs.
the non-healed group. CONCLUSIONS: VLU imposes signiﬁ-
cant medical costs and work productivity losses. Since the cost of
professional services is the main cost driver in the treatment of
VLU, new technologies that reduce the professional labor time
could signiﬁcantly reduce the economic burden of venous leg
ulcer. [1] Reilly MC, Zbrozek AS, Dukes EM. The validity and
reproducibility of work productivity and activity impairment
instrument. Pharmacoeconomics 1993;4:353–65.
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OBJECTIVES: This study aims to assess if hepatitis C patients
who had previously failed to achieve sustained virologic response
(SVR) following any hepatitis C treatment demonstrate different
patterns of health care utilization versus treatment-naïve patients
after peginterferon plus ribavirin (PR) therapy in the European
Union. METHODS: A retrospective chart review of hepatitis C
patients who received PR was conducted in the UK, Germany,
France, Italy, and Spain. Descriptive analyses reported standard-
ized annual rates of hospitalizations, emergency/accident visits
(EA), family physician/general practitioner visits (GP), specialist
visits (SP), and having 5 clinical tests (TESTS). Logistic regres-
sion models were applied to assess TF status impact on afore-
mentioned outcomes. RESULTS: 165 physicians collected data
for 615 patients (baseline data: mean age 43.7 years, 33%
female, 90% Caucasian, 85% genotype-1, 26% viral load
>1,000,000 IU/mL, 25% with prior treatment failure [TF]). PR
was administered for a median of 9.1 months (interquartile
range: 5.3–11.9); median post-treatment follow-up was 6.0
months (interquartile range: 2.0–10.0). Fewer TF patients
achieved SVR than treatment-naïve patients (43.3% versus
58.3%). Compared with treatment-naïve patients, TF patients
had signiﬁcantly more annual hospitalizations (1.7 versus 0.3),
EA (0.7 versus 0.2), GP (4.3 versus 2.0), SP (4.1 versus 2.3), and
TESTS (75% versus 85%) (p < 0.05 for all). When controlling
for confounding factors (age, weight, gender, genotype, time
between diagnosis and treatment initiation, alcohol intake, past
intravenous drug use, pre-treatment liver biopsy, steatosis, pre-
viral RNA, and SVR status), TF remained an independent risk
factor for signiﬁcant risk of hospitalization (OR = 4.33, 95%
CI = 2.38–7.87), EA (OR = 2.63, 95% CI = 1.49–4.76), GP
(OR = 3.45, 95% CI = 2.04–5.56), SP (OR = 2.86, 95%
CI = 1.72–4.76) and TESTS (OR = 2.04, 95% CI = 1.14–3.70).
Similar results were found in the genotype-1 patients. CONCLU-
SIONS: Hepatitis C patients who failed prior treatment demon-
strate higher health care resource use than treatment-naïve
patients after PR therapy, regardless of SVR status.
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OBJECTIVES: DUET 1&2 are two identically designed,
ongoing, randomized, double-blind, placebo-controlled, phase
III trials, which have demonstrated superiority of etravirine
(TMC125, ETR) + background regimen (BR) versus placebo +
BR in HIV-1-infected, treatment-experienced patients. This
analysis estimates the cost of the hospitalizations observed in
the DUET studies applied to a Belgian treatment setting.
METHODS: Hospitalization events and duration of hospital
stay were recorded for each patient in the DUET trials. Differ-
ences in hospitalizations and total days hospitalized at 48 weeks
were compared between ETR + BR and placebo + BR in the
pooled DUET population. Daily hospital costs were collected
from the Belgian IMS Hospital Disease database, a longitudinal
patient-level retrospective database. A sample of 277 HIV
patients with 397 hospitalizations in Belgium were extracted.
An average cost per day was calculated in 2007 Euros, which
included INAMI (health system cost) and patient contribution
costs for medications, procedures, and rooming charges. These
costs were applied to the total days observed in the DUET trials
to estimate overall hospital costs. RESULTS: A total of 1203
patients were included from the DUET trials: 599 vs. 604 in the
ETR vs. placebo groups. Baseline characteristics and average
follow-up were comparable between arms. The number (%) of
patients hospitalized was 105 (18%) for ETR + BR vs. 139
(23%) for placebo + BR, respectively (p = 0.0006). Total hospital
days observed during the 48 week follow-up period were 1702
for ETR + BR vs. 2747 for placebo + BR. The average cost per
patient day was estimated to be €556.39. Over the population,
total hospital costs were estimated to be €946,676 for ETR + BR
vs. €1,528,403 for placebo + BR. CONCLUSIONS: At Week 48,
ETR + BR provided a statistically signiﬁcant reduction the
number of patients hospitalized vs. placebo + BR. The reductions
in the number of hospitalizations and time spent in the hospital
represent clinical beneﬁt to the patients and signiﬁcant savings in
hospital-related costs to the health care system.
INFECTION—Patient-Reported Outcomes Studies
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OBJECTIVES: To assess the impact of communication between
physicians and patients living with HIV/AIDS on levels of treat-
ment adherence and patient satisfaction. METHODS: In a pre-
vious survey at our teaching hospital in Thailand we found good
adherence in 99% of patients, assessed by visual analogue scale.
This qualitative study was conducted between November 2007–
January 2008. The research comprised direct observations of
patient-health care provider encounters at the clinic and in-depth
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